- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02170519
Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide
Study Overview
Detailed Description
Phase 1- In the original study, 3 doses of Iloprost were given. This was revised after 5 subjects were enrolled in order to study the effects of continuous delivery over a longer period of time.
Phase 2 - All remaining subjects received Iloprost as a continuous treatment.
The study was designed for an enrollment of 200 subjects and was ended early.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical evidence of pulmonary hypertension (PH) requiring INO therapy as prescribed by the attending physician.
- Indwelling arterial catheter.
- Signed informed consent
Exclusion Criteria:
- Clinically unstable circulatory condition requiring epinephrine > 0.1 mcg/kg/min or levophed, or already meeting treatment failure criteria (see section 5.3 below)
- Known hypersensitivity to prostacyclin compounds
- Patients receiving sildenafil or bosentan
- Refusal by the attending physician
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 2: Inhaled Iloprost continuous
Each subject will have a stable dose of INO therapy as established by the attending physicians for at least one hour. Initial baseline data collection will then be made. A 20 mcg dose of Iloprost will be given initially. During this treatment there will be a nitric oxide titration to 0. Iloprost will be aerosolized continuously at a dose of 5-30mcg/hour for as long as the attending physician deems it necessary to deliver vasodilator therapy. |
A 20 mcg dose of Iloprost will be given initially.
Other Names:
|
Experimental: Phase 1: Inhaled Iloprost 3 doses
Each subject will have a stable dose of INO therapy as established by the attending physicians for at least one hour. Initial baseline data collection will then be made. A 20 mcg dose of Iloprost will be given initially. During this treatment there will be a nitric oxide titration to 0. Iloprost will be aerosolized three different times on hour apart. Thirty minutes after the last iloprost dose, INO will be added back at the previous (baseline) dose. |
A 20 mcg dose of Iloprost will be given initially.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change in Oxygen Saturation (SpO2) From Baseline
Time Frame: 30 mins after initial dose, every 2 hours as long as subject was on drug up to approximately 24 hours
|
Readings were taken from the medical record and the data may not have been present at the exact time frames.
|
30 mins after initial dose, every 2 hours as long as subject was on drug up to approximately 24 hours
|
Percent Change in Oxygen Saturation (SpO2) From Baseline
Time Frame: dose 1 (1 hour), dose 2 (2 hour), dose 3 (3 hour), combined therapy (4.5 - 5 hour), end INO (6 - 7 hour)
|
dose 1 (1 hour), dose 2 (2 hour), dose 3 (3 hour), combined therapy (4.5 - 5 hour), end INO (6 - 7 hour)
|
|
Change in Mean Heart Rate From Baseline
Time Frame: 30 mins after initial dose, every 2 hours as long as subject was on drug up to approximately 24 hours
|
30 mins after initial dose, every 2 hours as long as subject was on drug up to approximately 24 hours
|
|
Change in Mean Heart Rate From Baseline
Time Frame: dose 1 (1 hour), dose 2 (2 hour), dose 3 (3 hour), combined therapy (4.5 - 5 hour), end INO (6 - 7 hour)
|
dose 1 (1 hour), dose 2 (2 hour), dose 3 (3 hour), combined therapy (4.5 - 5 hour), end INO (6 - 7 hour)
|
|
Number of Treatment Failures
Time Frame: as long as subject was on drug up to approximately 24 hours
|
Treatment failure is defined as Central venous pressure (CVP) ≥ 20 mm Hg and any one of the following:
|
as long as subject was on drug up to approximately 24 hours
|
Change in Mean Pulmonary Artery Pressure (mPAP) From Baseline
Time Frame: 30 mins after initial dose, every 2 hours as long as subject was on drug up to approximately 24 hours
|
30 mins after initial dose, every 2 hours as long as subject was on drug up to approximately 24 hours
|
|
Change in Mean Pulmonary Artery Pressure (mPAP) From Baseline
Time Frame: dose 1 (1 hour), dose 2 (2 hour), dose 3 (3 hour), combined therapy (4.5 - 5 hour), end INO (6 - 7 hour)
|
dose 1 (1 hour), dose 2 (2 hour), dose 3 (3 hour), combined therapy (4.5 - 5 hour), end INO (6 - 7 hour)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Cardiac Output (CO) From Baseline
Time Frame: 30 mins after initial dose, every 2 hours as long as subject was on drug up to approximately 24 hours
|
30 mins after initial dose, every 2 hours as long as subject was on drug up to approximately 24 hours
|
|
Change in Cardiac Output (CO) From Baseline
Time Frame: dose 1 (1 hour), dose 2 (2 hour), dose 3 (3 hour), combined therapy (4.5 - 5 hour), end INO (6 - 7 hour)
|
dose 1 (1 hour), dose 2 (2 hour), dose 3 (3 hour), combined therapy (4.5 - 5 hour), end INO (6 - 7 hour)
|
|
Change in Mean Venous Oxygen Saturation (SvO2) From Baseline
Time Frame: 30 mins after initial dose, every 2 hours as long as subject was on drug up to approximately 24 hours
|
SvO2 represents an average of all the venous oxygen saturations of the various organs and tissues.
|
30 mins after initial dose, every 2 hours as long as subject was on drug up to approximately 24 hours
|
Change in Mean Venous Oxygen Saturation (SvO2) From Baseline
Time Frame: dose 1 (1 hour), dose 2 (2 hour), dose 3 (3 hour), combined therapy (4.5 - 5 hour), end INO (6 - 7 hour)
|
dose 1 (1 hour), dose 2 (2 hour), dose 3 (3 hour), combined therapy (4.5 - 5 hour), end INO (6 - 7 hour)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Neil MacIntyre, MD, Duke University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00013737
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Hypertension
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Heidelberg UniversityMerck Sharp & Dohme LLCRecruitingChronic Thromboembolic Pulmonary Hypertension | Primary Pulmonary Arterial HypertensionGermany
-
University of South FloridaWithdrawnPulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Idiopathic Pulmonary Arterial Hypertension | Primary Pulmonary HypertensionUnited States
-
BayerCompletedPrimary HypertensionChina
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
University of Kansas Medical CenterRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Hypertension Due to Left Heart Disease | Pulmonary Hypertension, Primary, 4 | Pulmonary Hypertension, Primary, 2 | Pulmonary Hypertension, Primary, 3 | Pulmonary Hypertension, Primary and other conditionsUnited States
-
Papworth Hospital NHS Foundation TrustMerck Sharp & Dohme LLCCompleted
-
University of ZurichCompletedPulmonary Hypertension | Pulmonary Artery Hypertension | Chronic Thromboembolic Pulmonary HypertensionSwitzerland
-
Mads ErsbøllRecruitingPulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionDenmark
Clinical Trials on Inhaled Iloprost
-
Heidelberg UniversityBayerWithdrawnPulmonary Hypertension | Chronic Left Ventricular FailureGermany
-
University of ChicagoTerminatedPulmonary HypertensionIsrael, United States
-
BayerCompletedPulmonary HypertensionTurkey
-
BayerCompletedHypertension, PulmonaryJapan
-
BayerCompleted
-
Yonsei UniversityNot yet recruitingMediastinal MassKorea, Republic of
-
Carmel Medical CenterUnknownChronic Obstructive Pulmonary DiseaseIsrael
-
Seoul St. Mary's HospitalThe Catholic University of KoreaCompletedLung CancerKorea, Republic of
-
BayerDra. Pilar Escribano Subías - Coordinator - HU 12 de Octubre - Madrid (Spain)Completed
-
Yonsei UniversityCompletedChronic Obstructive Pulmonary Disease | Video-assisted Thoracoscopic SurgeryKorea, Republic of